SPRAVATO® (esketamine) Treatment
We know your path isn’t always a straight line from where you are to where you want to be. We’re here to help you on your SPRAVATO® (esketamine) journey.
SPRAVATO® (esketamine) is currently available in California, Florida, and North Carolina. Call to schedule an appointment.
SPRAVATO® (esketamine) treatment at Mindpath Health
At Mindpath Health, we provide SPRAVATO® (esketamine) treatment for adults with treatment resistant depression. If psychiatry and therapy have not provided sufficient relief, esketamine can support your mental health journey.
What is SPRAVATO® (esketamine)?
SPRAVATO® (esketamine) is the only FDA-approved, self-administered nasal spray for adults with treatment-resistant depression. It is commonly prescribed with other treatments, such as antidepressant medications and therapy.
How effective is SPRAVATO® (esketamine) for treatment-resistant depression?
National data shows that about 50% of patients who undergo esketamine treatment report at least a 50% improvement in depressive symptoms. Approximately 30% of patients report achieving remission in depressive symptoms (minimal to no symptoms).
I have nothing but good things to say about the entire experience thus far, and I hope more patients will become aware of this treatment option and be able to take advantage of it.
– Mindpath Health patient
Mindpath Health SPRAVATO® (esketamine) treatment locations
Esketamine treatment is currently available in:
- California
- Florida
- North Carolina
What are the side effects of SPRAVATO® (esketamine)?
Occasionally, patients report side effects including:
- Mild sedation, drowsiness, or sleepiness
- Dissociation
- Nausea
- Elevated blood pressure
You may experience additional side effects which can be discussed with your clinician.
How long is SPRAVATO® (esketamine) treatment?
SPRAVATO® (esketamine) is self-administered twice weekly under the supervision of a clinician. After taking the medication, patients are observed in-office for two hours.
After the first four weeks of taking SPRAVATO® (esketamine), your clinician will determine the appropriate ongoing treatment schedule.
How do I begin SPRAVATO® (esketamine) treatment?
You may qualify for esketamine treatment if you are 18 years or older and have:
- Been diagnosed with major depressive disorder (MDD)
- Tried at least two antidepressants without success
If you qualify, a patient navigator will schedule a consultation and clinical evaluation to determine if SPRAVATO® (esketamine) is medically appropriate for you.
Current Mindpath Health patients should talk with their clinician for a referral before seeking SPRAVATO® (esketamine) treatment.
Frequently Asked Questions
SPRAVATO® (esketamine) is an FDA-approved, self-administered nasal spray for adults age 18 and older with treatment-resistant depression. It is commonly prescribed with other treatments, such as antidepressant medications and therapy.
SPRAVATO® (esketamine) is self-administered in-office under the supervision of a clinician. After taking the medication, patients are observed for two hours.
SPRAVATO® (esketamine) treatment may be covered by your insurance plan. Call 1-855-501-1004 to determine eligibility and whether the medication may be covered by insurance.
LEARN
